Table 2 Clinical characteristics and next-generation sequencing results
| Â | Histology | EGFR Sequence Variants | Frequency (%) | Allele Call | Exon 20 T790M | Frequency (%) | Conversion to SCLC | Prior TKIs | Duration (days) |
|---|---|---|---|---|---|---|---|---|---|
Case 1 | Adenocarcinoma | Exon 19 | 44.3 | Heterozygous | Yes | 7.2 | No | Erlotinib | 681 |
E746_T750 del | |||||||||
Case 2 | Adenocarcinoma | Exon 19 | 59.4 | Heterozygous | No | - | No | Gefitinib | 537 |
E746_T751 del > A | |||||||||
Case 3 | Adenocarcinoma | Exon 21 L858R | 46.1 | Heterozygous | No | - | No | Gefitinib | 195 |
Exon 18 T725R | 30.6 | Heterozygous | |||||||
Case 4 | Adenocarcinoma | Exon 21 L858R | 23.3 | Heterozygous | No | - | No | Erlotinib | 217 |
Exon 20 S768I | 10.0 | Heterozygous | |||||||
Case 5 | Adenocarcinoma | Exon21 L858R | 56.9 | Heterozygous | No | - | No | Gefitinib | 1105 |
Exon 18 E709G | 54.5 | Heterozygous | |||||||
Case 6 | Adenocarcinoma | Exon 19 | 97.2 | Homozygous | Yes | 21.8 | No | Erlotinib | 693 |
E746_T750 del | |||||||||
Case 7 | Adenocarcinoma | Exon 21 L858R | 13.8 | Heterozygous | Yes | 5.2 | No | Erlotinib | 537 |
Case 8 | Squamous cell carcinoma | Exon 19 | 86.9 | Heterozygous | Yes | 7.3 | No | Erlotinib | 315 |
E746_T750 del | |||||||||
Case 9 | Adenocarcinoma | Exon 19 | 65.3 | Heterozygous | Yes | 41.3 | No | Erlotinib | 1555 |
E746_T750 del | |||||||||
Case 10 | Adenocarcinoma | Exon21 L858R | 11.2 | Heterozygous | Yes | 4.8 | No | Gefitinib | 1912 |
Case 11 | Adenocarcinoma | Exon 19 | 46.4 | Heterozygous | Yes | 11.0 | No | Erlotinib | 256 |
E746_T750 del | |||||||||
Case 12 | Adenocarcinoma | Exon21 L858R | 22.2 | Heterozygous | No | - | No | Erlotinib | 924 |
Exon 21 G873R | 10.8 | Heterozygous | |||||||
Case 13 | Adenocarcinoma | Exon 21 L861Q | 59.9 | Heterozygous | No | - | No | Gefitinib Erlotinib | 1304 122 |
Exon 20 P772S | 10.2 | Heterozygous | |||||||
Exon19 L747S | 11.8 | Heterozygous | |||||||
Exon2 A289V | 12.3 | Heterozygous | |||||||
Case 14 | Adenocarcinoma | Exon 19 | 80.82 | Heterozygous | Yes | 14.8 | No | Erlotinib | 392 |
E746_T750 del | Â | Â | |||||||
Case 15 | Adenocarcinoma | Exon21 L858R | 76.7 | Heterozygous | Yes | 10.3 | No | Erlotinib | 339 |